Benign Prostatic Hyperplasia Therapeutics Market Current Trends and Future Aspect Analysis 2013 - 2019

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy, is a urological disorder that involves proliferation of the cellular components of the prostrate. BPH is the most common form of neoplasm in men. BPH results in the formation of large nodes and nodules in the periurethral region of the prostate. The significantly large nodules compresses the urethral canal that causes to partial or complete urinary tract obstruction which inhibits the normal flow of urine. Obstruction in the urinary tract further leads to complications such as urinary retention, urinary tract infections and urinary hesitancy.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1872

Geographically, North America is the leading market due to high prevalence rate of benign prostatic hyperplasia and lower urinary tract symptoms (LUTS). Various studies reports that 90% of men in the U.S., aged between 45 and 80 years suffer from some type of LUTS and approximately 14 million men in the U.S. have symptoms of BPH. Asia-Pacific is also expected to witness a significant growth due to the rise in various urological disorders and complications. However, BPH tends to be more progressive in African-American men owing to the presence of high testosterone level in their body.

Rise in geriatric population is expected to be one of the major driver that might drive the market. Additionally, increased awareness for prostate cancer and other urological disorders, are also expected to fuel the growth of the global BPH therapeutics market.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1872

However, high adoption rate of minimally invasive surgeries such as transurethral microwave thermotherapy (TUMT), laparoscopic prostatectomy and transurethral needle ablation (TUNA) might impede the growth of the BPH therapeutics market.

Some of the key players in the benign prostatic hyperplasia (BPH) therapeutics Market are AEternaZentaris Inc., Astellas Pharma Inc., Eli Lilly and Company, EndoCeutics, Inc., IntelGenx Technologies Corp., Ipsen S.A., Nymox Pharmaceutical Corporation, Protox Therapeutics Inc. and Quest PharmaTech Inc.

Request for the TOC of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1872

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.